JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. ODTX | 0.00 |
JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:
ODTX) with a Overweight rating and announces Price Target of $26.
